Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection (Lipodox®) in Chinese Patients

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Bioequivalence study is proposed to be carried out on patients of breast cancer/ ovarian cancer, who are administrated for Doxorubicin Hydrochloride Liposomal Injection Lipodox® or Caelyx® in a dose of 50 mg/m2.
Epistemonikos ID: 9b37ab224924fb57cb1c600588d47c382da2e084
First added on: May 10, 2024